<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126620</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-042</org_study_id>
    <secondary_id>CDR0000437855</secondary_id>
    <secondary_id>NCI-7178</secondary_id>
    <nct_id>NCT00126620</nct_id>
  </id_info>
  <brief_title>Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking blood flow&#xD;
      to the tumor and by blocking some of the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib and&#xD;
      erlotinib in treating patients with metastatic or unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of sorafenib and&#xD;
           erlotinib in patients with metastatic or unresectable solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the optimal biologically effective dose of this regimen that will lead to&#xD;
           hypophosphorylation of epidermal growth factor receptor (EGFR), ERK, Akt, and vascular&#xD;
           endothelial growth factor receptor (VEGFR), and inhibition of angiogenesis and apoptosis&#xD;
           with tolerable toxicity in these patients.&#xD;
&#xD;
        -  Correlate the pharmacokinetic profiles of this regimen with toxicity and biological&#xD;
           activity in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate phosphorylation status of EGFR, ERK, Akt, and VEGFR with antitumor activity of&#xD;
           this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study.&#xD;
&#xD;
      Patients receive oral sorafenib alone once or twice daily on days -6 to 0*. Patients then&#xD;
      receive oral sorafenib once or twice daily and oral erlotinib once daily on days 1-28.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Not considered part of course 1; considered a &quot;run-in&quot; period only.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sorafenib and erlotinib until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are&#xD;
      treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then at least&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 5-14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended phase II dose</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic outcomes</measure>
    <time_frame>Pre study and cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcomes</measure>
    <time_frame>Pre-study, cycle 1 and cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Every 8 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of EGFR, AKT, ERK and VEGFR with antitumor activity</measure>
    <time_frame>If responses or prolonged stable disease are observed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGFR activating mutations, gene amplification status, EGFR intron 1 polymorphism if responses or prolonged disease stabilization are seen</measure>
    <time_frame>If responses or prolonged stable disease are observed</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <arm_group_label>OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <arm_group_label>OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Standard curative or palliative measures do not exist OR are no longer effective&#xD;
&#xD;
          -  Measurable disease by radiography (for patients treated at the maximum tolerated dose&#xD;
             [MTD] only)&#xD;
&#xD;
          -  Tumor accessible for serial biopsies (for patients treated at the MTD only)&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis or coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  PT INR ≤ 1.5 unless on full-dose warfarin&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 140 mm Hg or&#xD;
             diastolic BP &gt; 90 mm Hg despite medication)&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Ophthalmic&#xD;
&#xD;
          -  No abnormalities of the cornea, including any of the following:&#xD;
&#xD;
               -  Dry eye syndrome&#xD;
&#xD;
               -  Sjögren's syndrome&#xD;
&#xD;
               -  Congenital abnormalities (e.g., Fuch's dystrophy)&#xD;
&#xD;
               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or&#xD;
                  Bengal-Rose)&#xD;
&#xD;
               -  Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production&#xD;
                  test)&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active peptic ulcer disease that would impair the ability to swallow pills&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             a requirement for IV alimentation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to undergo serial biopsies, positron emission tomography, and CT scanning (for&#xD;
             patients treated at the MTD only)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No significant traumatic injury within the past 3 weeks&#xD;
&#xD;
          -  No history of allergic reaction to drugs of similar chemical or biological composition&#xD;
             to study drugs&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other condition that would impair the ability to swallow pills&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic colony-stimulating factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy (except for low dose, non-myelosuppressive&#xD;
             radiotherapy) and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedure affecting absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior sorafenib or erlotinib&#xD;
&#xD;
          -  No other prior agents targeting Raf, vascular endothelial growth factor (VEGF), VEGF&#xD;
             receptor, or epidermal growth factor receptor&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or&#xD;
             phenobarbital)&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers (e.g., rifampin or Hypericum perforatum [St. John's&#xD;
             wort])&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin) allowed&#xD;
             provided PT INR &lt; 1.1 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR &gt; 1.5 allowed&#xD;
             provided both of the following criteria are met:&#xD;
&#xD;
               -  Patient has an in range INR (between 2-3) while on a stable-dose of oral&#xD;
                  anti-coagulant OR a stable-dose of low molecular weight heparin&#xD;
&#xD;
               -  No active bleeding OR pathological condition that would confer a high risk of&#xD;
                  bleeding (e.g., tumor involving a major vessel or known varices)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian L. Siu, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2.</citation>
    <PMID>20197396</PMID>
  </results_reference>
  <results_reference>
    <citation>Duran I, Hotté SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2007 Aug 15;13(16):4849-57.</citation>
    <PMID>17699864</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

